CytomX Therapeutics, Founded At UCSB, Queues Up For IPO

CytomX Therapeutics, a biotech startup which was founded by UC Santa Barbara professor Patrick Daugherty, and which has a significant number of Southern California angel investors, filed for an IPO last week, saying that it is looking to raise $100M on the NASDAQ Global Market. The company hopes to trade under the symbol CTMX. The IPO is being underwritten by BofA Merrill Lynch, Jefferies, Cowen and Company, and Oppenheimer & Co. The company's institutional investors include Third Rock Ventures, Canaan Partners, Roche Venture Fund, Casdin Capital, Cormorant Asset Management, Deerfield Management, Fidelity Management & Research Company, Perceptive Advisors, Pfizer Venture Investments, Redmile Group, Tekla Healthcare Investors, Tekla Life Sciences Investors, Venrock Healthcare Capital Partners and Wellington Management Company. CytomX was initially capitalized by a group of Southern California angel investors, right after it was launched out of UCSB, according to a number of those investors.